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Abstract
Background: Cervical cancer is one of the top causes of cancer morbidity and mortality in Colombia despite the
existence of a national preventive program. Screening coverage with cervical cytology does not explain the lack of
success of the program in reducing incidence and mortality rates by cervical cancer. To address this problem an
ecological analysis, at department level, was carried out in Colombia to assess the relationship between cervical
screening characteristics and cervical cancer mortality rates.
Methods: Mortality rates by cervical cancer were estimated at the department level for the period 2000-2005.
Levels of mortality rates were compared to cervical screening coverage and other characteristics of the program. A
Poisson regression was used to estimate the effect of different dimensions of program performance on mortality
by cervical cancer.
Results: Screening coverage ranged from 28.7% to 65.6% by department but increases on this variable were not
related to decreases in mortality rates. A significant reduction in mortality was found in departments where a
higher proportion of women looked for medical advice when abnormal findings were reported in Pap smears.
Geographic areas where a higher proportion of women lack health insurance had higher rates of mortality by
cervical cancer.
Conclusions: These results suggest that coverage is not adequate to prevent mortality due to cervical cancer if
women with abnormal results are not provided with adequate follow up and treatment. The role of different
dimensions of health care such as insurance coverage, quality of care, and barriers for accessing health care needs
to be evaluated and addressed in future studies.
Background
Cervical screening is considered a highly effective inter-
vention that has led to a 70% reduction in mortality by
cervical cancer in developed countries [1]. By contrast,
Latin America and the Caribbean have failed to impact
cervical cancer mortality rates in spite of the implemen-
tation of universal screening [2]. Incidence rates of cer-
vical cancer in Latin America and the Caribbean (age
adjusted rate = 29.2 per 10
5) are higher than in any
other region in the world except Africa [3].
Colombia has a cervical cancer screening program
since 1975 but it has been unsuccessful in significantly
reducing cervical cancer incidence or mortality [4]. One
of the potential causes for this failure is the introduction
of managed health care system in 1993. The Colombian
health system is supposed to provide universal health
insurance coverage within two regimes: 1) The Contrib-
utory Regime, mainly administered by private compa-
nies, that covers formally employed and independent
workers who contribute to the scheme. Contributions
are collected by the insurer of choice. 2) The Subsidized
Regime, administered by public institutions or private
companies, covers the poor and indigent individuals
who cannot afford to make any insurance contribution.
Both regimes have a basic benefits package, but the
mandatory health care plan (POS, sp. Plan Obligatorio
de Salud) for the contributory regime includes every
level of care while the mandatory health care plan for
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Subsidiado) is complemented with services provided by
public hospitals and financed through traditional sup-
ply-side subsidies [5]. In this system, there is consider-
able fragmentation of activities between private and
public actors with a weak role of supervision and regula-
tion by the Ministry of Health. In addition, it provides
little room for centralized activities and the cervical can-
cer screening program has been unable to adapt to this
changing reality [6].
There are, at least, two critical components of a cervi-
cal screening program, coverage and follow up activities.
Several reports have described that ensuring an ade-
quate follow up of women with Pap smears abnormal-
ities is very important to decrease the incidence of
cervical cancer and deaths due to it [7]. Yabroff et al
(2003) identified barriers of access to follow up after
abnormal screening results arising from health provi-
ders, patients and from the health system itself [8]. The
likelihood of detecting cervical cancer in advanced
stages or even dying due to it is increased by those
barriers.
Screening coverage is commonly used as the only
indicator to evaluate the success of cervical cancer
screening programs. However, screening is just a part of
them, therefore screening programs must be evaluated
for the full range of services needed to prevent cervical
cancer and reduce cervical cancer mortality. In the pre-
sent study, a range of data sources related to quality of
the cervical cancer screening program in Colombia were
analyzed to provide evidence for our argument.
Methods
Colombia is a middle income South American country
with 46 million inhabitants. It is divided in 32 depart-
ments plus the capital district, Bogotá.
Study design
An ecological analysis was carried out comparing rates
of cervical cancer mortality with screening coverage and
follow up indicators at the departmental level.
Dependent variable
Mortality rates by cervical cancer were estimated using
the 2000-2004 mortality records from the National
Department of Statistics (DANE, sp. DepartamentoAd-
ministrativoNacional de Estadisticas). National mortality
information is routinely collected and analyzed by
DANE using individual records of every person
deceased. DANE makes estimations of under registry by
department using information collected from national
census [9]. Mortality rates were adjusted using the Ben-
nett- Horiuchi method. The following codes of death
were included: C530, Malignant neoplasm of the endo-
cervix; C531, Malignant neoplasm of the exocervix;
C538, Overlapping lesion of cervix uteri; C539, Cervix
uteri, unspecified; and C55X, Malignant neoplasm of
uterus, part unspecified (10th ICD). To address potential
misclassification bias the following algorithm was used,
cervical cancer deaths = cervical cancer deaths registered
+ a* deaths by uterine cancer of unspecified part+
b*deaths by cancer of corpus uteri; a =0 . 9a n db =0 . 3 .
Values for a and b were obtained and adapted from
Loos et al [10].
Variables related to cervical cancer screening. The fol-
lowing variables were extracted from the National Sur-
vey of Demography and Health (ENDS, sp. Encuesta
Nacional de Demografía y Salud) [11], all proportions
were estimated by department: proportion of women
who reported having a cervical cytology once a year,
proportion of women who have never had a cervical
cytology, proportion of women with an abnormal cervi-
cal cytology who contacted their health care provider to
receive treatment and proportion of women who did
not collect the results of their last cytology. The ENDS
is carried out every five years using a stratified polietapic
probabilistic sample of 37,211 households. In 2005, the
survey collected information from 41,344 women within
ages 13 to 49 years and had a response rate from 88%
to 92% depending on the geographical unit. An addi-
tional variable included in the analysis was the propor-
tion of women covered by any of the health insurance
regimes by department. Health insurance status was
used to adjust the effect of screening variables on mor-
tality since access to screening and mortality may vary
by insurance status.
Analysis
The 33 departments were classified according to values
of mortality and screening characteristics. They were
grouped within 4 categories according to the frequency
of cervical cancer mortality (0-9.9 per10
5, 10.4-12.7
per10
5, 12.9-15.6 per 10
5, and 16.0-21.8 per10
5.) Vari-
ables related to cervical cancer screening were also cate-
gorized by quartiles. Tables were used to make cross
comparative analysis between mortality and cervical can-
cer screening characteristics. Poisson regression models
were built to examine the strength of the association
between rates of mortality and categories of screening
coverage, proportion of women looking for treatment,
and proportion of women who do not collect results.
Results of Poisson regression are given as incidence rate
ratios (IRR) with 95% confidence intervals [12].
Since we used aggregated national data we were not
required to be approved by an institutional review
board.
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Between 2000 and 2004, an average of 2918 annual
deaths due to cervical cancer was reported by DANE
(Table 1). The proportion of women undertaking a con-
ventional cervical cytology once a year was 47.5%. Only
13.7% of the women interviewed have never had a pap
smear.
Most women collected the results of cervical screening
and looked for medical advice when cervical abnormal-
ities were reported. The largest proportion of women
who failed to collect the results was in Boyacá (17.4%)
which also had the lowest proportion of women looking
for medical advice when cervical abnormalities were
reported (64%) (Table 1).
Table 1 Distribution of cervical cancer mortality rates (2000-2004) and indicators of cervical cancer screening
programs








Amazonas 14,633 5 16.0 39.4 9.7 87.7 17.2 25.4
Antioquia 1,695,093 353 12.7 47.3 6.7 88.4 8.9 28.3
Arauca 58,004 16 14.5 50.2 7.3 86.5 18.5 26.1
Atlántico 627,571 143 13.5 38.9 6.4 85,7 20.3 35.2
Bogotá 2,173,732 473 13.9 54.3 8.9 74.2 10.1 18.9
Bolívar 514,680 98 10.7 36.7 4.9 82.9 19.8 38.6
Boyacá 357,138 65 10.4 43.1 17.4 64.6 17 21
Caldas 298,632 107 21.8 57.3 12.5 82.4 10.9 31.6
Caquetá 104,560 27 13.5 44.3 12.0 79.0 17.5 41
Casanare 72,240 15 11.1 51.9 7.4 88.6 16.2 37
Cauca 336,097 78 12.7 49.9 15.6 83.8 21.1 42.1
Cesar 231,167 56 12.9 34.8 7.5 86.6 18.2 38
Chocó 104,910 10 4.5 36.1 9.0 84.2 16.4 37.4
Córdoba 384,543 87 12.4 34.8 3.9 87.5 16.5 48.7
Cundinamarca 618,658 97 9.0 49.7 10.2 81.3 15.8 19.4
Guainía 7,514 1 6.3 37.0 14.9 100.0 14.3 14.8
Guaviare 19,799 3 7.1 40.7 12.8 88.9 12.5 19.2
Huila 263,798 79 16.4 48.2 10.8 73.6 12.8 42.4
La Guajira 157,054 19 6.3 28.7 5.0 88.3 18.3 40.2
Magdalena 299,679 63 11.3 30.9 9.8 88.1 22.3 45.2
Meta 206,687 71 19.7 46.4 10.9 84.1 12.8 36.8
Nariño 417,498 105 14.1 54.7 13.9 81.0 15.5 24.2
Norte de Santander 345,178 95 15.6 40.9 5.5 83.2 20.3 45.4
Putumayo 73,462 10 6.8 65.6 5.1 90.4 10.4 23.7
Quindío 165,207 56 20.9 61.9 8.4 82.9 9.6 31
Risaralda 278,130 90 20.0 51.4 9.3 83.0 9 37.4
San Andrés Island 21,356 3 8.7 59.9 6.9 71.4 9.4 12.8
Santander 580,869 140 14.3 52.4 11.1 83.3 12.4 26.8
Sucre 201,907 46 12.4 32.1 5.3 78.3 19.8 40.2
Tolima 381,515 141 21.1 44.7 7.0 76.5 15.3 38
Valle 1,273,844 365 17.6 48.8 6.0 85.5 10.2 30.7
Vaupés 8,492 0 0.0 33.1 13.4 100.0 22.4 9.6
Vichada 11,862 1 3.9 45.2 11.7 90.2 10.3 22.2
1. Proportion of women who reported having a cervical cytology once a year
2. Proportion of women who did not collect the results of their last cytology
3. Proportion of women with an abnormal cervical cytology who contacted their health care provider to receive treatment
4. Proportion of women who have never had a cervical cytology
5. Proportion of uninsured population
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those departments where more women were covered by
screening. By contrast, the proportion of women looking
for treatment after an abnormal result was associated
moderately with mortality by cervical cancer. A protec-
tive effect was observed when the proportion of women
looking for treatment was higher than 81%, IRR 0.65
IC95 % (0.56 - 0.76), this association remained signifi-
cant after adjusting by screening coverage or health
insurance coverage. An important increase in cervical
cancer mortality was observed in areas where the pro-
portion of women without health insurance was higher
than 22%, IRR 1.66 IC95% (1.42 - 1.95);(Table 2).
Discussion and Conclusions
This analysis suggests that cervical cancer screening
coverage was not protective against cervical cancer mor-
tality in Colombia as it has been shown in several
reports [4,13,14]. Instead, the proportion of women who
complied with follow up after an abnormal cytology was
statistically associated to cancer mortality. After adjust-
ing by health insurance coverage, those areas with the
highest percent of women who contacted their health
care provider after an abnormal result had almost 40%
less mortality than the areas with the lowest proportion.
Several alternatives have been proposed to increase
the adherence to follow up and treatment of women
with an abnormal result in a Pap smear. Yabroff et al
(2000) conducted a meta-analysis of different strategies
to increase compliance to follow up after an abnormal
cervical cancer screening. They found that cognitive
interventions, telephone confirmation of appointments,
were more effective than sociological or behavioral
interventions. Combining behavioral, cognitive and
sociological strategies yielded inconsistent results. Indivi-
dual studies also support the efficacy of cognitive inter-
ventions [15]. Engelstead et al tested a combination of
outreach community visits with counseling and tele-
phone calls in a group of women in Oakland CA, USA.
They found that this strategy increased the adherence to
follow up and abnormalities treatment by more than
90% [7]. Marcus et al reported that providing women
with transportation incentives and a personalized follow
up letter also increase adherence to follow up visits [16].
Table 2 Results of Poisson regression analysis given as incidence rate ratios (IRR)
Range Mortality Rate by cervical cancer IRR (CI 95%) Adjusted IRR (CI 95%) *
1. Proportion of women who have never had a cervical cytology
8.9 - 10.4 22.5 -
10.9 - 15.5 19.9 1.05 (0.95 - 1.15) 0.86 (0.78 - 0.96)
15.8 - 18.2 25.5 0.82 (0.72 - 0.93) 0.68(0.57 - 0.80)
18.3 - 22.4 24.3 0.93 (0.84 - 1.02) 0.71(0.61 - 0.82)
2. Proportion of women who had an abnormal cervical cytology and contacted their health care provider to receive treatment
64.6 - 81.0 23.9 - -
81.3 - 83.8 24.3 1.01 (0.92 - 1.11) 0.88(0.79 - 0.98)
84.1 - 87.7 25.8 1.08 (0.98 - 1.18) 0.88 (0.77 - 1.01)
88.1 - 100 19.9 0.83 (0.74 - 0.93) 0.65 (0.56 - 0.76)
3. Proportion of uninsured women
9.6 - 22.2 20.0 - -
23.7 - 31.0 21.2 1.23 (1.11 - 1.35) 1.47 (1.27 - 1.69)
31.6 - 38.0 22.3 1.44 (1.29 - 1.61) 1.77 (1.54 - 2.03)
38.6 - 48.7 23.4 1.14 (1.02 - 1.27) 1.66 (1.42 - 1.95)
4. Proportion of women who have a cervical cytology once a year
28.7 - 36.7 19.9 -
37.0 - 44.7 25.8 1.30 (1,13 - 1,48)
45.2 - 50.2 23.7 1.19 (1,06 - 1,34)
51.4 - 65.6 24.5 1.23 (1,09 - 1,38)
5. Proportion of women who did not collect the results of their last cytology
3.9 - 6.4 24.0 -
6.7 - 8.9 23.2 0.96 (0,88 - 1,05)
9.0 - 11.1 23.4 0.98 (0,88 - 1,08)
11.7 - 17.4 25.2 1.04 (0,92 - 1,19)
*Adjusted by variables 1, 2, 3 included in the final model.
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vital statistics since misclassification in death causes
may occur. However, more than 90% of deaths by uter-
ine cancer in Colombia were classified as cervical cancer
which made that explanation implausible. On the other
hand, women answering the survey may have given
equivocal answers to questions about use of health ser-
vice related to cervical cancer screening, this potential
source of error, would produce a non-differential mis-
classification bias resulting in an underestimation of the
association between cytology coverage and cervical can-
cer mortality. Nonetheless, ENDS surveys have been car-
ried out for more than 20 years in Colombia using
similar instruments; surveyors are well trained and have
experience applying these questions. In addition, Caplan
et al 2003 have found that self-reporting of cervical can-
cer screening test utilization is highly accurate compared
with information extracted from medical records (over-
all agreement > 80%) [17]. Therefore, we believe that
self-reporting bias on use of screening services would be
unlikely to mask a strong effect of cytology coverage on
cervical cancer mortality in our study.
A potential explanation for the lack of relationship
between coverage and cervical cancer mortality lies on
how the Colombian Health system is structured. People
in the contributory regime receive the most complete
package of services while those in the subsidized regime
are entitled to receive a more limited package of ser-
vices. Until 2005 colposcopy and cervix biopsy were not
provided to subsidized or uninsured people. Yabroff et
al (2003) has reported that there are barriers for access
to follow up after cervical screening that arise from
health providers. Two of the most important are being
uninsured or underinsured, and the perception that fol-
low up procedures are too expensive. Specific studies on
barriers for access to follow up after cervical screening
are needed in Latin America [8]
Recent studies have addressed the deleterious effect of
the health care reform in Colombia upon several indica-
tors of health situation. Ruiz et al has described how the
Colombian health system has been unable to reduce
maternal mortality while Chile, where public hospitals
have been strengthened, has lowered mortality rates by
more than 70% [18]. However, we were unable to for-
mally test the role of health providers in the magnitude
of death rate by cervical cancer since we had no access
to information on the health insurance status of indivi-
dual women. This is another potential shortcoming of
our analysis.
The results presented here suggest that cervical can-
cer screening programs should not be evaluated based
on the number of smears taken per year only. Other
indicators such as quality of smear samples, propor-
tion of cervical lesions confirmed using biopsy or
colposcopy, compliance with follow up, and percent of
women effectively treated among those with cervical
abnormalities should also be used. Some have pro-
posed HPV detection as a complementary service to
improve cervical cancer screening. Gamboa et al [19].
assessed the cost effectiveness of introducing HPV
DNA detection tests in Colombia concluding that it
would reduce cervical cancer mortality and would be
very cost-effective. However, including the test would
only complicate further the screening process that
already seems to be failing in providing basic services
of follow up.
Colombia is currently considering the introduction of
HPV vaccination in girls as a measure to improve the
prevention and control of cervical cancer. One impor-
tant barrier for HPV vaccination in middle income
countries is the current price of available HPV vaccines.
Goldie et al (2007) has shown that for an average Latin
American country prices above USD$50 per vaccine
dose are hard to be affordable though vaccination would
be cost effective [20]. Other aspect to consider is
whether a booster of vaccine is needed to meet the goal
of cervical cancer reduction. If vaccine boosters are
needed then the cost effectiveness ratio of vaccines
would become less attractive. Once vaccine prices
become more affordable, a combination of universal
vaccination and strengthening of the cervical cancer
screening program would become the ideal health policy
to control cervical cancer.
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